Kerry Costello Email

VP, Apitegromab Program Lead (Spinal Muscular Atrophy) . Scholar Rock

Current Roles

Employees:
190
Revenue:
$18.2M
About
Scholar Rock® is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
Scholar Rock Address
301 Binney Street
Cambridge, MA
United States
Scholar Rock Email

Past Companies

Scholar RockVice President, Apitegromab Program Lead (Spinal Muscular Atrophy)
Scholar RockSenior Director, Commercial Development (all pipeline)
Kerry Costello Consulting, LLCPrincipal

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.